Hikal Ltd vs Ind Swift Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 12, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 179.95 as of 12 Jun 11:41 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 years The revenue of Hikal Ltd for the Mar '26 is ₹ 526 crore as compare to the Dec '25 revenue of ₹ 497.1 crore. This represent the growth of 5.81% The revenue of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 172.01 crore as compare to the Dec '25 revenue of ₹ 178.43 crore. This represent the decline of -3.6% The ebitda of Hikal Ltd for the Mar '26 is ₹ 64.9 crore as compare to the Dec '25 ebitda of ₹ 47.5 crore. This represent the growth of 36.63% The ebitda of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 17.64 crore as compare to the Dec '25 ebitda of ₹ 25.9 crore. This represent the decline of -31.89% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ 14.4 crore over 8 quarters. This represents a CAGR of 68.03% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 15.11 crore over 8 quarters. This represents a CAGR of 286.79% The Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 yearsThe Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

FAQs for the comparison of Hikal Ltd and Ind-Swift Laboratories Ltd

Which company has a larger market capitalization, Hikal Ltd or Ind-Swift Laboratories Ltd?

Market cap of Hikal Ltd is 2,157 Cr while Market cap of Ind-Swift Laboratories Ltd is 1,377 Cr

What are the key factors driving the stock performance of Hikal Ltd and Ind-Swift Laboratories Ltd?

The stock performance of Hikal Ltd and Ind-Swift Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Ind-Swift Laboratories Ltd?

As of June 12, 2026, the Hikal Ltd stock price is INR ₹174.95. On the other hand, Ind-Swift Laboratories Ltd stock price is INR ₹158.35.

How do dividend payouts of Hikal Ltd and Ind-Swift Laboratories Ltd compare?

To compare the dividend payouts of Hikal Ltd and Ind-Swift Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.